In vitro susceptibilities of Candida spp. to panomycocin, a novel exo-β-1,3-glucanase isolated from Pichia anomala NCYC 434

Microbiology and Immunology

Volumn 51, Issue 9, 2007, Pages 797-803

  Izgü, Fatih ^a   Altinbay, Demet ^a   Türeli, Akif Emre ^a  

^a MIDDLE EAST TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Candida species; Exo 1,3 glucanase; Susceptibility testing; Yeast killer toxin

Indexed keywords

ANTIFUNGAL AGENT; GLUCAN SYNTHASE; PANOMYCOCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA PSEUDOTROPICALIS; CANDIDA TROPICALIS; FUNGUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; PICHIA ANOMALA;

EID: 34548817561     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2007.tb03975.x     Document Type: Article

References (36)

1. Bartizal, C., and Odds, F.C. 2003. Influences of methodological variables on susceptibility testing of caspofungin against Candida species and Aspergillus fumigatus. Antimicrob. Agents Chemother. 47: 2100-2107.
2. Bevan, E.A., and Makower, M. 1963. The physiological basis of the killer character in yeast. Proc. 11th Int. Cong. Gene 1: 202-203.
3. Bobek, L.A., and Situ, H. 2003. MUC 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action. Antimicrob. Agents Chemother. 47: 643-652.
4. Bradford, M.A. 1976. Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
5. Canton, E., Peman, J., Gobernado, M., Viudes, A., and Espinel-Ingroff, A. 2004. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob. Agents Chemother. 48: 2477-2482.
6. Clinical and Laboratory Standards Institute. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A, Clinical and Laboratory Standards Institute, Wayne, Pa.
7. Dereinski, S.C., and Stevens, D.A. 2003. Caspofungin. Clin. Infect. Dis. 36: 1445-1457.
8. Devkatte, A.N., Zore, G.B., and Karuppayil, S.M. 2005. Potential of plant oils as inhibitors of Candida albicans growth. FEMS Yeast Res. 5: 867-873.
9. Disney, M.D., Constantine, G.H., and Douglas, H.T. 2002. Uptake and antifungal activity of oligonucleotides in Candida albicans. Proc. Natl. Acad. Sci. U.S.A. 100: 1530-1534.
10. Espinol-Ingroff, A., Warnock, D.W., Vazquez, J.A., and Arthington-Skaggs, B.A. 2000. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. Med. Mycocl. Suppl. 1: 293-304.
11. Hacek, D.M., Noskin, G.A., Trakas, K., and Peterson, L.R. 1995. Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory. J. Clin. Microbiol. 33: 1884-1889.
12. Hazen, K.C. 1995. New and emerging yeast pathogens. Clin. Microbial Rev. 8: 462-478.
13. Hossain, A.G., and Ghannoum, M.A. 2001. New developments in chemotherapy for non-invasive fungal infections. Expert Opin. Invest. Drug. 10: 1501-1511.
14. İzgü, F., and Alt?nbay, D. 2004. Isolation and characterization of the K5-type yeast killer protein and its homology with an exo-β-1,3-glucanase. Biosci. Biotechnol. Biochem. 68: 685-693.
15. İzgu, F., Alt?nbay, D., and Sertkaya, A. 2005. Enzymic activity of the K5-type yeast killer toxin and its characterization. Biosci. Biotechnol. Biochem. 69: 2200-2206.
16. İzgu, F., Alt?nbay, D., and Türeli, E.A. 2007. In vitro activity of panomycocin, a novel exo-β-1,3 glucanase isolated from Pichia anomala NCYC 434, against dermatophytes. Mycoses 50: 31-34.
17. Marr, K.A., Rustad, T.R., Rex, J.H., and White, T.C. 1999. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob. Agents Chemother. 43: 1383-1386.
18. Panda, D., Rathinasamy, K., Manas, K.S., and Wilson, L. 2005. From the cover: kinetic suppression of microtubule dynamic instability by griseofulvin: implications for its possible use in the treatment of cancer. Proc. Natl. Acad. Sci. U.S.A. 102: 9548-9553.
19. Pfaller, M.A., Messer, S.A., Boyken, L., Huynh, H., Hollis, R.J., and Diekema, D.J. 2002. In vitro activities of 5-fluorocytosine against 8803 clinical isolates of Candida spp.: global assessment of primary resistance using national committee for clinical laboratory standards susceptibility testing methods. Antimicrob. Agents Chemother. 46: 3518-3521.
20. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., and Diekema, D.J. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44: 760-763.
21. Pfaller, M.A., Boyken, L., Hollis, R.J., Messer, S.A., Tendolkar, S., and Diekema, D.J. 2006. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. J. Clin. Microbiol. 44: 3533-3538.
22. Pfeiffer, I., Golubev, W.I., Farlas, Z., Kucsera, J., and Golubev, N. 2004. Mycocin production in Cryptococcus aquaticus. Antonie Leeuwenhoek 86: 369-375.
23. Ramani, R., and Chaurvedi, V. 2000. Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test. Antimicrob. Agents Chemother. 44: 2752-2758.
24. Reeves, E.P., Murphy, T., Daly, P., and Kavanagh, K. 2004. Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus. J. Med. Microbiol. 53: 719-725.
25. Ryder, N.S., Wagner, S., and Leitner, I. 1998. In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts. Antimicrob. Agents Chemother. 42: 1057-1061.
26. Sangorrin, M.P., Zajonskovsky, I.E., and Lopez, C.A. 2001. Killer behaviour in wild wine yeasts associated with Merlot and Malbec type musts spontaneously fermented from north western Patagonia (Argentina). J. Basic Microbiol. 41: 105-113.
27. Schmitt, M.J., and Breinig, F. 2002. The viral killer system in yeast: from molecular biology to application. FEMS Microbiol. Rev. 26: 257-276.
28. Sheehan, D.J., H?tchcock, C.A., and Sibley, C.M. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12: 40-79.
29. Selitrennikoff, C.P. 2001. Antifungal proteins. Appl. Environ. Microbiol. 67: 2883-2894.
30. Staib, F. 1999. The green colour effect (GCE) of the killer strain Cryptococcus laurentii CBS 139 on Staib agar. Mycoses 42: 103-106.
31. Takemoto, K., Yamamoto, Y., and Ueda, Y. 2006. Evaluation of antifungal pharmacodynamic characteristics of AmBisome against Candida albicans. Microbiol. Immunol. 50: 579-586.
32. Venkatesan, P., Perfect, J.R., and Myers, S.A. 2005. Evaluation and management of fungal infections in immunucompromised patients. Dermatol. Ther. 18: 44-57.
33. Walker, G.M., McLeod, A.H., and Hodgson, V.J. 1995. Interactions between killer yeasts and pathogenic fungi. FEMS Microbiol. Lett. 127: 213-222.
34. Wickner, R.B. 1979. The killer double stranded RNA plasmids of yeast. Plasmid 2: 303-322.
35. Yap, N.A., Lopes, B., Langridge, P., and Henschke, P.A. 2000. The incidence of killer activity of non-Saccharomyces yeasts towards indigenous yeast species of grape must: potential application in wine fementation. J. Appl. Microbiol. 89: 381-389.
36. Young, T.W., and Yagiu, M.A. 1978. A comparison of the killer character in different yeasts and its classification. Antonie Leewenhoek 44: 59-77.